CORRECTION article

Front. Bioeng. Biotechnol., 02 June 2025

Sec. Nanobiotechnology

Volume 13 - 2025 | https://doi.org/10.3389/fbioe.2025.1623425

Corrigendum: Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

This article is a correction to:

  1. Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

    1. Read original article
Weiwei Zeng&#x;Weiwei Zeng1†Yuning Luo&#x;Yuning Luo1†Dali GanDali Gan1Yaofeng ZhangYaofeng Zhang1Huan DengHuan Deng1Guohui Liu Guohui Liu2*
  • 1Department of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, China
  • 2Shenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China

A Corrigendum on
Advances in doxorubicin-based nano-drug delivery system in triple negative breast cancer

by Zeng W, Luo Y, Gan D, Zhang Y, Deng H and Liu G (2023). Front. Bioeng. Biotechnol. 11:1271420. doi: 10.3389/fbioe.2023.1271420

In the published article, there were two errors.

A correction has been made to Abstract.

This sentence previously stated:

“Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer.”

The corrected sentence appears below:

“Triple negative breast cancer (TNBC) is one of the most aggressive breast cancer.”

A correction has been made to Introduction, Paragraph one.

This sentence previously stated:

“Triple positive breast cancer (TPBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”

The corrected sentence appears below:

“Triple negative breast cancer (TNBC) is a specific type of breast cancer that lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and accounts for approximately 15% of all breast cancer cases.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: doxorubicin, nanocarriers, triple negative breast cancer, drug delivery, clinical

Citation: Zeng W, Luo Y, Gan D, Zhang Y, Deng H and Liu G (2025) Corrigendum: Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer. Front. Bioeng. Biotechnol. 13:1623425. doi: 10.3389/fbioe.2025.1623425

Received: 06 May 2025; Accepted: 12 May 2025;
Published: 02 June 2025.

Edited and reviewed by:

Qingxin Mu, University of Washington, United States

Copyright © 2025 Zeng, Luo, Gan, Zhang, Deng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Guohui Liu, bGdoNTk3N0AxNjMuY29t

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.